RO5313534 + memantine

RO5313534 + memantine is an investigational combination of RO5313534 (also known as MEM3454) and memantine, studied primarily for potential use in Alzheimer's disease. RO5313534 (MEM3454) is a nicotinic acetylcholine receptor agonist, evaluated as an adjunct treatment to donepezil for cognitive symptoms in Alzheimer's. Memantine is an NMDA receptor antagonist approved for moderate to severe Alzheimer's dementia; it works by blocking excessive glutamate activity that can lead to neurotoxicity. Preclinical and clinical trials have evaluated the pharmacokinetics, safety, and tolerability of combining these agents, but there is no approved fixed-dose product containing both. Both are small molecules acting via distinct central nervous system targets relevant to dementia. RO5313534 development was sponsored by Hoffmann-La Roche. Memantine is marketed in various countries by different manufacturers, including under the brand names Namenda, Axura, Ebixa, Marixino, and Namzaric (the latter in combination with donepezil but not with RO5313534)[3][4][5].

Other names

MEM3454 + memantine